To confirm that MS-275–potentiated tumor killing transcended LCMV GP33–41 epitope recognition, we investigated whether tumor-infiltrating endogenous CD8+ T cells derived from ACT+MS-275–treated mice could recognize and kill parental B16F10 cells, which do not express LCMV GP33–41. Here, CD8A is linked to neoplasm.